From owner-cypherpunks@Algebra.COM  Fri Dec 21 02:02:26 2001
Return-Path: <owner-cypherpunks@Algebra.COM>
Received: from pacific-carrier-annex.mit.edu (PACIFIC-CARRIER-ANNEX.MIT.EDU [18.7.21.83])
	by positron.mit.edu (8.11.6/8.9.3) with ESMTP id fBL72BS23573
	for <kwantam@positron.mit.edu>; Fri, 21 Dec 2001 02:02:11 -0500
Received: from ak47.algebra.com (ak47.algebra.com [208.233.99.160])
	by pacific-carrier-annex.mit.edu (8.9.2/8.9.2) with ESMTP id CAA05805
	for <rsw@mit.edu>; Fri, 21 Dec 2001 02:01:59 -0500 (EST)
Received: from ak47.algebra.com (localhost [127.0.0.1])
	by ak47.algebra.com (8.12.1/8.12.1) with ESMTP id fBL6orC5007434
	for <cypherpunks-outgoing@ak47.algebra.com>; Fri, 21 Dec 2001 00:50:53 -0600
Received: (from majordom@localhost)
	by ak47.algebra.com (8.12.1/8.12.1/Submit) id fBL6or6k007433
	for cypherpunks-outgoing; Fri, 21 Dec 2001 00:50:53 -0600
X-Authentication-Warning: ak47.algebra.com: majordom set sender to owner-cypherpunks@Algebra.COM using -f
Received: from einstein.ssz.com (cpunks@einstein.ssz.com [204.96.2.99])
	by ak47.algebra.com (8.12.1/8.12.1) with ESMTP id fBL6n5C5007373
	for <cypherpunks@algebra.com>; Fri, 21 Dec 2001 00:49:07 -0600
Received: (from cpunks@localhost)
	by einstein.ssz.com (8.8.8/8.8.8) id AAA16568
	for cypherpunks@algebra.com; Fri, 21 Dec 2001 00:54:13 -0600
Received: (from mdom@localhost)
	by einstein.ssz.com (8.8.8/8.8.8) id AAA16557
	for cypherpunks-outgoing; Fri, 21 Dec 2001 00:54:07 -0600
Received: from s6.ezzi.net ([208.23.118.240])
	by einstein.ssz.com (8.8.8/8.8.8) with ESMTP id AAA16549
	for <cypherpunks@ssz.com>; Fri, 21 Dec 2001 00:52:50 -0600
From: twaddle@post.com
Received: from consultant-com.mr.outblaze.com [216.191.161.212] by s6.ezzi.net with ESMTP
  (SMTPD32-7.04) id A81797A60158; Fri, 21 Dec 2001 01:35:03 -0500
Message-ID: <00006c6c6fd9$00000994$000009cd@ob-mail-com.mr.outblaze.com>
To: <cypherpunks@highlight.com>, <cypgrp@cypgrp.com>, <cypher@cacomp.com>,
   <cyp@infinitytx.net>, <cypher@grgig.net>, <cypembpow@sysnet.net>,
   <cypher@roxboro.net>, <cyperthug@journalist.com>, <cyphert@cyberis.net>,
   <cypher@bigfoot.com>, <cypher@appz.com>, <cypherpunk@rosa.com>,
   <cyphermag@stkgroup.com>, <cypher@madmanmark.com>, <cyphers@grsinc.com>,
   <cyphered@ik.com>, <cypher@cynapse.com>, <cypher42@melvin.net>,
   <cypher@stagecast.com>, <cypher@fidalgo.net>, <cypher@infinite.com>,
   <cypatrol@sunandmoon.com>, <cypherpunks@einstein.ssz.com>,
   <cypert@juno.com>, <cypagent@centuria.com>
Cc: <cyphen@alliance.net>, <cyphi@groupz.net>, <cypher@hishouse.com>,
   <cypher@netsol.net>, <cypages@tripod.net>, <cypher@cypher.com>,
   <cypher75@okay.net>, <cyphers@marshill.com>, <cypert@prairienet.com>,
   <cypcove@suncove.com>, <cyp@skypoint.net>, <cypherpunks@cyberpass.net>,
   <cypfgll@kj.net>, <cypher@intermediainc.com>, <cypher@bankvault.com>,
   <cypher@sfol.com>, <cypher@compuware.com>, <cypherpunks@openpgp.net>,
   <cypherphreak@gopenguin.com>, <cypherm@ideafit.com>, <cypher@bigplanet.com>,
   <cyperangel@fortunecity.com>, <cypherpunks@toal.com>,
   <cypher@totalchaos.net>, <cypher@gig.net>
Old-Subject: CDR: Sign Up and make over 786% per annum on your investments.                23475
Date: Fri, 21 Dec 2001 00:20:44 -1800
MIME-Version: 1.0
Content-Type: text/html;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Reply-To: cypherpunks@einstein.ssz.com
X-Mailing-List: cypherpunks@ssz.com
X-Unsubscription-Info: http://einstein.ssz.com/cdr
X-List-Admin: list@ssz.com
X-Loop: ssz.com
X-Acceptable-Languages: English, Russian, German, French, Spanish
Subject:  Sign Up and make over 786% per annum on your investments.                23475
X-Algebra: <A HREF=http://www.algebra.com>Algebra</A>
Sender: owner-cypherpunks@Algebra.COM
Precedence: bulk
X-Mailing-List: cypherpunks@algebra.com
X-List-Admin: ichudov@algebra.com
X-Loop: cypherpunks@algebra.com
X-spam: 100 
Status: O
Content-Length: 25553
Lines: 606


<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">

<html>
<head>
	<title>Untitled</title>
</head>

<body>
<TABLE bgColor=3D#ffffff border=3D0 cellPadding=3D3 cellSpacing=3D0 width=3D=
561 style=3D"WIDTH: 579px; HEIGHT: 792px">
  
  
  <TR>
    <TD bgColor=3D#0000f0><FONT color=3D#ffffff size=3D4 
     ><STRONG>A 
      Note from the Editor:</STRONG></FONT></TD></TR>
  <TR>
  
              
            
    <TD bgColor=3D#ffffff>
      <BLOCKQUOTE><STRONG><FONT size=3D4> <P align=3Djustify>    <BR></FON=
T><FONT size=3D2>Before you 
        discard this e-mail as Junk, you should read the next few paragrap=
hs 
        about our impressive rate of return on the featured companies. If =
you 
        would have been fortunate enough to receive our featured companies=
 at 
        the time we featured them, you would have taken a $ 1000 investmen=
t to 
        $8,860 in a span of 12 months (An increase of over 786%).&nbsp; Ho=
w? 
        Easy.&nbsp; Buy when we feature a company, sell when it peaks (usu=
ally 
        within first sixty days or less) and invest all or part of it into=
 our 
        next feature</FONT></STRONG>. </P>
        <P align=3Djustify><U><STRONG>Here is an example of what has happe=
ned in 
        last few months:</STRONG> </U></P>
        <P>
        <OL>
          <LI>
          <DIV align=3Djustify><FONT size=3D2><STRONG><FONT 
          color=3D#008000>XMSR</FONT>, feature price about $4.00 in April =
2001 
          peaked at around $17 and stayed between $12 to $15 until middle =
of 
          August. </STRONG><STRONG></FONT></DIV>
          <LI><FONT size=3D2>
          <DIV align=3Djustify><FONT color=3D#008000>TBXR</FONT>, feature =
price of about $1 in June 
          2001 peaked at around $ 2.80 and stayed above $ 2 until middle o=
f 
          July. </STRONG></FONT><STRONG></DIV></LI></OL><FONT 
        size=3D2>
        <P></P>
		
		
        <P align=3Djustify>These are some of the companies. 
        Our subscribers buy at our feature time and sell at their discreti=
on a 
        while later at much higher prices. </STRONG></FONT></P>
        <P><STRONG></P>
		<FONT size=3D2>
        <P align=3Djustify><FONT color=3D#ff0000><FONT color=3D#000000>We =
all know 
        that leaving our money in the bank only returns a small </FONT>3% =
to 5% 
        annually. </FONT>With using our featured companies, buying the 
        stock at the right time and selling them when it has moved up, you=
 can 
        lock up the profits.&nbsp; </STRONG></FONT></P>
        <STRONG>
         <P align=3Djustify><FONT size=3D2>If you are interested in receiv=
ing more of 
        our features, click to the sign up section below and we will add y=
ou to 
        our OPT-IN list. Meanwhile here is our next feature. Happy investi=
ng. 
        Remember investing is risky and we are not investment 
        advisors(disclaimer).You can sign up by e-mailing me at </FONT><A 
        href=3D"mailto:mac12344b@yahoo.com">mac12344b@yahoo.com</A><FONT 
        size=3D2>.<BR><BR></FONT></STRONG><FONT size=3D4><EM><U><STRONG>NO=
W OUR 
        FEATURE PRESENTATION</STRONG> <BR><BR></U></EM></FONT><STRONG><FON=
T 
        size=3D2>This feature represents a tremendous investment opportuni=
ty. Our 
        featured company is a very compelling investment choice. With its 
        current price this company is extremely undervalued and based on E=
PS 
        projections a price target could be reached in the near future.</F=
ONT><BR></P></STRONG></BLOCKQUOTE></TD></TR>
  <TR>
    <TD bgColor=3D#0000f0>
      <P align=3Dleft><FONT color=3D#ffffff><B>INVESTORS SEEK SHELTER IN 
      BIOTECHS</B> </FONT></P></TD></TR>
  
  <TR>
    <TD bgColor=3D#0000f0><STRONG>
      <P align=3Dcenter></STRONG><FONT color=3D#ffffff 
      size=3D5><STRONG>  Samaritan Pharmaceuticals(OTCBB:SPHC) 
      </STRONG></FONT></P></TD></TR>
  <TR>
    <TD bgColor=3D#ffffff>     
       </TD></TR>
  <TR>
    <TD align=3Dleft vAlign=3Dtop>
      <TABLE border=3D0 cellPadding=3D3 cellSpacing=3D0 width=3D555>
        
        <TR>
          <TD align=3Dleft height=3D336 vAlign=3Dtop width=3D275>
            <TABLE border=3D0 cellPadding=3D3 cellSpacing=3D0 width=3D265>
              
              <TR bgColor=3D#0000ff>
                <TD colSpan=3D2>
                  <P align=3Dleft class=3DMsoNormal style=3D"TEXT-ALIGN: c=
enter"><FONT color=3D#ffffff><SPAN 
                  style=3D"FONT-FAMILY: Arial"><STRONG> REASONS TO 
                  BUY</STRONG></SPAN></FONT></P></TD></TR>
              <TR>
                <TD align=3Dleft vAlign=3Dtop width=3D247></TD></TR></TABL=
E>
            <TABLE border=3D0 cellPadding=3D3 cellSpacing=3D0 width=3D265>
              
              <TR>
                <TD align=3Dright height=3D34 vAlign=3Dtop width=3D10>
				<FONT color=3D#006633 size=3D"2"><B>1.</B></FONT>
				</TD>
                <TD height=3D34 vAlign=3Dtop width=3D247>
				<p align=3D"justify">
                  <STRONG><FONT size=3D"2"><b>SPHC hits milestone completi=
on of phase 
                  Iib Clinical Trial for ANTICORT in Patients With HIV 
                  Infection. This drug could be the First Low Cost Drug fo=
r AIDS. This study was conducted under an IND filed with  the US FDA. (Aug=
 17 /PRNewswire)</b></FONT></STRONG> 
				</p>
                </TD>
			  </TR>
              <TR>
                <TD align=3Dright vAlign=3Dtop width=3D10>
				<FONT color=3D#006633 size=3D2><B>2</FONT>.</B></TD>
                <TD align=3Dleft vAlign=3Dtop width=3D247>
				<p align=3D"justify">
                  <STRONG><FONT size=3D"2"><b>				
				     
                       SPHC recently licensed a 
                  Early Detection Breast Cancer Patent which Identifies Pr=
otein (PBR) Responsible for 
                  Part of Cellular Changes in the Development and 
                  Progression Of Breast Cancer.</STRONG> </p></B></FONT>
                         
                           
                        
                  </TD></TR>
              <TR>
                <TD align=3Dright vAlign=3Dtop width=3D10><FONT color=3D#0=
06633 
                   
                  size=3D2><B>3.</B></FONT></TD>
                <TD align=3Dleft vAlign=3Dtop width=3D247>				<p align=3D"=
justify">
                  <STRONG><FONT size=3D"2"><b> 
                    SPHC recently entered into a&nbsp; Seven 
                  year exclusive partnership agreements with Georgetown 
                  University..</b></FONT>
                            
                         </p></STRONG>
						   </TD></TR></TABLE>
            <TABLE border=3D0 cellPadding=3D3 cellSpacing=3D0 width=3D265>
              
              <TR>
                <TD align=3Dright vAlign=3Dtop width=3D10><FONT color=3D#0=
06633 
                  size=3D2><B>4.</B></FONT></TD>
                <TD align=3Dleft vAlign=3Dtop width=3D247>
                  <P align=3Djustify><STRONG><FONT size=3D2><B>SPHC recent=
ly entered 
                  into a exclusive license with Georgetown for a patent 
                  concerning the early detection of Alzheimer=FFFFFF92s an=
d other 
                  neurodegenerative diseases by detecting increases in oxi=
dative 
                  stress in the 
brain</B></FONT></P></STRONG></TD></TR></TABLE>
            <TABLE border=3D0 cellPadding=3D3 cellSpacing=3D0 width=3D265>
              
              <TR>
                <TD align=3Dright vAlign=3Dtop width=3D10><FONT color=3D#0=
06633 
                  size=3D2><B>5.</B></FONT></TD>
                <TD align=3Dleft vAlign=3Dtop width=3D247>
                  <P align=3Djustify><STRONG><FONT size=3D2><B>SPHC announ=
ced on 
                  September 6, that it was granted an exclusive worldwide 
                  licensing agreement to commercialize a =FFFFFF93Choleste=
rol 
                  Recognition Amino Acid Sequence=FFFFFF94 Patented Invent=
ion for 
                  Georgetown 
            University.</B></FONT></P></STRONG></TD></TR></TABLE><BR>
            <TABLE border=3D0 cellPadding=3D3 cellSpacing=3D0 
            style=3D"WIDTH: 267px; HEIGHT: 159px" width=3D265>
              
              <TR bgColor=3D#0000ff>
                <TD colSpan=3D2>
                  <P align=3Dcenter><FONT 
                  face=3D"Times New Roman, Times, serif"></FONT><FONT 
                  color=3D#ffffff><STRONG><FONT 
                  color=3D#ffffff face=3DArial size=3D4><B><FONT 
                  size=3D3>AMAZING 
                  REVENUES:</FONT></B></FONT></STRONG></FONT></P></TD></TR=
>
              <TR>
                <TD colSpan=3D2>
				<P align=3Djustify><b><font color=3D"teal" size=3D"2"><FONT color=3D#0=
00000>SPHC's &nbsp;drug 
                  Anticort completed late stage FDA Phase Ib/IIa clinical =
human 
                  trials for HIV at the LA Aids Research Alliance and plan=
s to 
                  submit final "study report" to FDA early 2002. 
                  <STRONG></FONT><FONT size=3D2><FONT size=3D3><BR><BR><FO=
NT 
                  color=3D#000000>SPHC</FONT></FONT><FONT color=3D#000000>=
 and 
                  Georgetown University signed a seven-year research 
                  collaboration to discover, develop, and commercialize no=
vel 
                  therapies for Alzheimer's and Cancer. 
                  </FONT></FONT></STRONG></P>
                  <P><STRONG><FONT size=3D2><FONT color=3D#000000 
                  size=3D3>SPHC&nbsp;</FONT></FONT></STRONG><STRONG><FONT 
                  color=3D#000000>expanded its drug portfolio beyond Antic=
ort and 
                  has identified drug candidates for Alzheimer's and other=
 
                  neurodegenerative disorders, now in pre-clinical 
                  trials</FONT>.</STRONG></P>
                  <P align=3Djustify></FONT></B></P></TD></TR></TABLE></TD=
>
          <TD align=3Dleft height=3D336 vAlign=3Dtop width=3D229>
            <TABLE border=3D0 cellPadding=3D4 cellSpacing=3D0>
              
              <TR>
                <TD align=3Dmiddle bgColor=3D#003399 height=3D118 vAlign=3D=
center>
                  <TABLE bgColor=3D#ffffff border=3D0 cellPadding=3D0 cell=
Spacing=3D0 
                  width=3D260>
                    
                    <TR>
                      <TD align=3Dleft height=3D101 vAlign=3Dtop>
                        <TABLE border=3D0 cellPadding=3D4 cellSpacing=3D0 =
width=3D282>
                          
                          <TR>
                            <TD width=3D164><FONT color=3D#6666cc><B><FONT=
 
                              face=3D"Verdana, Geneva, Helvetica, Arial, s=
ans-serif" 
                              size=3D1>SYMBOL</FONT><FONT 
                              size=3D1>:</FONT></B></FONT></TD>
                            <TD width=3D102>
                              <P align=3Dcenter><STRONG>SPHC</STRONG></P><=
/TD></TR>
                          <TR>
                            <TD width=3D164><STRONG><FONT 
                              color=3D#6666cc face=3DVerdana size=3D2>Curr=
ent 
                              Price:</FONT></STRONG></TD>
                            <TD width=3D102>
                              <P align=3Dcenter><STRONG>.16</STRONG></P></=
TD></TR>
                          <TR>
                            <TD width=3D164><FONT 
                              color=3D#6666cc 
                              face=3D"Verdana, Geneva, Helvetica, Arial, s=
ans-serif" 
                              size=3D1><B>52 WEEK HIGH/LOW:</B></FONT></TD=
>
                            <TD width=3D102>
                              <P align=3Dcenter>&nbsp;$<STRONG> 
                              1.03- .11</STRONG></P></TD></TR>
                          <TR>
                            <TD width=3D164><FONT 
                              color=3D#6666cc 
                              face=3D"Verdana, Geneva, Helvetica, Arial, s=
ans-serif" 
                              size=3D1><B>FLOAT (est.)</B></FONT></TD>
                            <TD width=3D102>
                              <P align=3Dcenter><FONT color=3D#6666cc 
                              ><B 
                              ><FONT face=3DVerdana 
                              size=3D2>&nbsp;</FONT><FONT color=3D#000000>=
<FONT 
                              face=3DVerdana><FONT 
                              size=3D2><STRONG>&nbsp;10,700,000</STRONG></=
FONT></FONT></FONT> </B></FONT></P></TD></TR>
                          <TR>
                            <TD width=3D164><FONT 
                              color=3D#6666cc 
                              face=3D"Verdana, Geneva, Helvetica, Arial, s=
ans-serif" 
                              size=3D1><B>SHARES OUTSTANDING</B></FONT></T=
D>
                            <TD width=3D102>
                              <P align=3Dcenter>&nbsp; 
                              <STRONG><STRONG><STRONG><FONT 
                              face=3DArial 
                              size=3D2><STRONG>26,000,000</STRONG></FONT><=
/STRONG></STRONG></STRONG></P></TD></TR>
                          <TR>
                            <TD height=3D20 width=3D164><FONT color=3D#666=
6cc 
                              face=3D"Verdana, Geneva, Helvetica, Arial, s=
ans-serif" 
                              size=3D1><B>12 MONTH PRICE PROJ.:</B></FONT>=
</TD>
                            <TD height=3D20 width=3D102>
                              <P 
                          align=3Dcenter><STRONG>$4.00</STRONG></P></TD></=
TR></TABLE>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
                        <A href=3D"http://finance.yahoo.com/q?s=3DSPHC.OB&=
amp;d=3Dt" 
                        target=3D_blank 
                        title=3Dhttp://finance.yahoo.com/q?s=3DSPHC.OB&amp=
;d=3Dt><FONT face=3DArial><STRONG>Quote</STRONG></FONT></A><FONT 
                        color=3D#0000ff face=3DArial ><STRONG> - 
                        </STRONG></FONT><A 
                        href=3D"http://biz.yahoo.com/n/s/sphc.ob.html" 
                        target=3D_blank 
                        title=3Dhttp://biz.yahoo.com/n/s/sphc.ob.html><FON=
T face=3DArial><STRONG>News</STRONG></FONT></A></TD></TR></TABLE></TD></TR=
>
              <TR>
                <TD align=3Dleft vAlign=3Dcenter>
                  <TABLE border=3D0 cellPadding=3D3 cellSpacing=3D0 width=3D=
265 
                  style=3D"WIDTH: 284px; HEIGHT: 395px">
                    
                    <TR bgColor=3D#006633>
                      <TD colSpan=3D2><FONT color=3D#ffffff 
                        face=3D"Times New Roman, Times, serif" 
                       ><B> 
                        Most Recent Developments:</B></FONT></TD></TR>
                    <TR>
              
                   
                      <TD align=3Dright height=3D34 vAlign=3Dtop width=3D1=
0><FONT 
                        face=3D"Verdana"
                             
                        size=3D2 
                           
                        ><B>1.</B></FONT></TD>
                      <TD align=3Dleft height=3D34 vAlign=3Dtop width=3D24=
7>
                        <P><A 
                        href=3D"/wsc2/Autoflag.html?Button=3DGet+Story&amp=
;DB=3DSQL&amp;SID=3D320b5776&amp;Symbol=3DSPHC"><FONT 
                        color=3D#000000 face=3DArial size=3D2>11/16/2001 0=
4:59 am 
                        Samaritan To Collaborate With the French Governmen=
t to 
                        Develop New Drugs and Diagnostic Tools by Using Re=
levant 
                        Resources Available in Fran</FONT> 
                                
                                 
                             
                        </A></P></TD></TR>
                    <TR>
                      <TD align=3Dright vAlign=3Dtop width=3D10><FONT face=
=3D"Verdana, 
                        &#13;&#10; &#13;&#10; &#13;&#10; Geneva, Helvetica=
, 
                        Arial, 
                        &#13;&#10;                        sans-serif" 
                        size=3D2><B>2.</B></FONT></TD>
                      <TD align=3Dleft vAlign=3Dtop width=3D247><FONT face=
=3D"Arial, 
                        &#13;&#10; &#13;&#10; &#13;&#10; 
                        Helvetica, 
                        &#13;&#10;                        sans-serif" 
                        size=3D2><B><P align=3Dleft>                      =
         
                                           
                               
                                
                         </B></FONT>&nbsp;<FONT 
                        class=3Dnwstdt> <A 
                        href=3D"/wsc2/Autoflag.html?Button=3DGet+Story&amp=
;DB=3DSQL&amp;SID=3D319u1355&amp;Symbol=3DSPHC"><FONT 
                        face=3DArial size=3D2 
                        color=3D#000000>11/15/2001 02:40 pm 10QSB: SAMARIT=
AN 
                        PHARMACEUTICALS INC</FONT></A></FONT></P></TD></TR=
>
                    <TR>
                      <TD align=3Dright vAlign=3Dtop width=3D10><FONT face=
=3D"Verdana, 
                        &#13;&#10; &#13;&#10; &#13;&#10; Geneva, Helvetica=
, 
                        Arial, 
                        &#13;&#10;                        sans-serif" 
                        size=3D2><B>3.</B></FONT></TD>
                      <TD align=3Dleft vAlign=3Dtop width=3D247><FONT face=
=3D"Arial, 
&#13;&#10;&#13;&#10;&#13;&#10;&#13;&#10;&#13;&#10;&#13;&#10;sans-serif" 
                        size=3D2><B><P align=3Djustify>  
                                
                               
                             
                        </B></FONT>&nbsp;<A 
                        href=3D"/wsc2/Autoflag.html?Button=3DGet+Story&amp=
;DB=3DSQL&amp;SID=3D310u5414&amp;Symbol=3DSPHC"><FONT 
                        face=3DArial size=3D2 
                        color=3D#000000>11/6/2001 05:31 am SAMARITAN 
                        PHARMACEUTICALS INC - Samaritan Victorious -- Awar=
ded 
                        Summary Judgment Wins $100,000 Cash - Bond Posted =
by 
                        Alfred T. Sapse</FONT></A><FONT face=3DArial 
                        size=3D2>  
                               <STRONG> 
                        .</STRONG></FONT></P></TD></TR></TABLE>  
                  </TD></TR></TABLE></TD></TR></TABLE><FONT size=3D4 color=
=3D#ffffff><B>
      <P align=3Dcenter>
      <TABLE bgColor=3D#0000ff border=3D0 cellPadding=3D2 cellSpacing=3D0 =
width=3D565 style=3D"WIDTH: 573px; HEIGHT: 25px">
        
        
        <TR>
          <TD align=3Dmiddle bgColor=3D#0000ff width=3D545>
            <P align=3Dleft><FONT 
            color=3D#ffffff face=3DArial><STRONG>About Samaritan Pharmaceu=
ticals: 
            </STRONG></FONT></P></TD></TR></TABLE></P>
      <DIV align=3Dleft></B></FONT><STRONG>SPHC is a 
      biopharmaceutical company focused on the commercialization of 
      =FFFFFF93=FFFFFF94drug candidates and =FFFFFF93diagnostics=FFFFFF94 =
to combat Alzheimer, Cancer 
      and HIV.&nbsp; Samaritan=FFFFFF92s drug candidate, Anticort complete=
d FDA Phase 
      1b/2a Clinical human trials for HIV and company plans 
      to submit its final Phase ll =FFFFFF93study report=FFFFFF94 to the F=
DA early 2002.&nbsp; 
      SPHC has established research collaboration with Georgetown Universi=
ty giving 
      it a research arm&nbsp;to develop new drug candidates and 
      diagnostics.&nbsp; The Company has an existing portfolio of 
      three licensed =FFFFFF93drug candidates=FFFFFF94. One of the drugs i=
n the 
      late stage FDA clinical trials and three =FFFFFF93drug candidates=FF=
FFFF94&nbsp; are in 
      the pre-clinical stages, including an Alzheimer and Breast Cancer Di=
agnostic drug.&nbsp; 
      SPHC has a financial partner in Fusion 
      Capital who has provided&nbsp;SPHC with an equity line of 20 million=
 dollars which 
      gives the Company cash, and more importantly, enough 
      money to fund its Clinical trials.</STRONG></DIV></TD></TR>
  <TR>
    <TD>
      <P><STRONG></P></STRONG></TD></TR>
  <TR>
    <TD align=3Dleft vAlign=3Dtop>
      <P align=3Dcenter><FONT size=3D4><STRONG>
      <TABLE bgColor=3D#0000ff border=3D0 cellPadding=3D2 cellSpacing=3D0 =
width=3D550 style=3D"WIDTH: 574px; HEIGHT: 25px">
        
        <TR>
          <TD align=3Dmiddle bgColor=3D#0000ff width=3D545><FONT color=3D#=
ffffff 
            face=3DArial 
      size=3D4><B>CONCLUSION:</B></FONT></TD></TR></TABLE></STRONG></FONT>=
</P><STRONG><FONT 
      color=3D#008080><FONT 
      color=3D#000000>The Key to successful investing is finding value in 
      something today that will be recognized by the investment community =
in the 
      future. <FONT face=3D"Times New Roman" size=3D3>SPHC </FONT>is one o=
f those 
      investments. For the last several years it has been developing it's 
      products and they are very close to going to market with these drugs=
 
      </FONT><FONT size=3D2><FONT face=3DArial><FONT color=3D#000000><STRO=
NG>Projected 
      Income to <FONT face=3D"Times New Roman" size=3D3>SPHC</FONT> upon d=
rug 
      approval is expected to exceed</STRONG><STRONG>$43 Million &nbsp;in =
the 
      first year and is expected to reach $ 85 Million in the 
      t</STRONG></FONT><STRONG><FONT color=3D#000000>hird Year. We beleive=
 <FONT 
      face=3D"Times New Roman" size=3D3>SPHC </FONT>has a very major upsid=
e in the 
      near term</FONT>.&nbsp;</STRONG></FONT></FONT></FONT> 
                  
              </STRONG></TD></TR>
  <TR>
    <TD align=3Dleft height=3D45 vAlign=3Dtop><FONT 
      color=3D#ffffff face=3DArial size=3D4><B>:
      <TABLE bgColor=3D#0000ff border=3D0 cellPadding=3D2 cellSpacing=3D0 =
width=3D550 style=3D"WIDTH: 573px; HEIGHT: 25px">
        
        <TR>
          <TD align=3Dmiddle bgColor=3D#0000ff width=3D545><FONT color=3D#=
ffffff 
            face=3DArial 
           ><B>Disclaimer:</B></FONT></TD></TR></TABLE></B></FONT></TD></T=
R>
  <TR>
    <TD align=3Dleft vAlign=3Dtop>
      <P><P align=3Djustify>Certain statements contained in this news rele=
ase may be 
      forward-looking statements within the meaning of The Private Securit=
ies 
      Litigation Reform Act of 1995. These statements may be identified by=
 such 
      terms as "expect", "believe", "may", "will", and "intend" or similar=
 
      terms. We are NOT a registered investment advisor or a broker dealer=
 This 
      is NOT an offer to buy or sell securities. No recommendation that th=
e 
      securities of the companies profiled should be purchased, sold or he=
ld by 
      individuals or entities that learns of the profiled companies. This =
is an 
      independent electronic publication that was paid $5,000 in cash by a=
 third 
      party for the electronic dissemination of this company information. =
Be 
      advised that investments in companies profiled are considered to be 
      high-risk and use of the information provided is for reading purpose=
s 
      only. If anyone decides to act as an investor they are advised not t=
o 
      invest without the proper advisement from an attorney or a registere=
d 
      financial broker, if any party decides to participate as an investor=
 then 
      it will be that investor's sole risk. Be advised that the purchase o=
f such 
      high-risk securities may result in the loss of some or all of the 
      investment. The companies that are profiled provide all information =
and 
      make no representations. The profiled companies make no warranties o=
r 
      guarantees as to the accuracy or the completeness of the disclosure.=
 
      Investors should not rely solely on the information presented. Rathe=
r, 
      investors should use the information provided by the profiled compan=
ies as 
      a starting point for doing additional independent research on the pr=
ofiled 
      companies in order to allow the investor to form his or her own opin=
ion 
      regarding investing in the profiled companies. Factual statements ma=
de by 
      the profiled companies are made as of the date stated and are subjec=
t to 
      change without notice. The receipt of this information shall not cre=
ate, 
      under any circumstances, any implication that there has been no chan=
ge in 
      the affairs of the company profiled since the date of review. Invest=
ing in 
      micro-cap securities is highly speculative and carries an extremely =
high 
      degree of risk. It is possible that an investor's entire investment =
may be 
      lost or impaired due to the speculative nature of the companies prof=
iled. 
      All information provided by the profiled companies may include infor=
mation 
      provided by outside sources, such as research reports, public filing=
s or 
      computer databases and information obtained from public information 
      available on the company. </P>
      <P><BR></P>
      <P align=3Dcenter><STRONG><FONT size=3D2>To unsubscribe from this ma=
iling, 
      </FONT><A href=3D"mailto:mac12344b@yahoo.com"><FONT size=3D2>CLICK H=
ERE</FONT> 
      </A><FONT size=3D2>to be removed.</FONT> </STRONG></P>
      <P><BR><FONT face=3DArial size=3D1><STRONG>&nbsp;</P></STRONG></FONT=
>
      <P>&nbsp;</P></TD></TR></TABLE>



</body>
</html>



